SMN1 Gene Replacement Market 2025: Increasing SMA Population Propels Therapeutic Demand | Biogen, Novartis AG, F. Hoffmann-La Roche Ltd

According to DataM Intelligence research, "the Global SMN1 Gene Replacement Market was valued at USD 1.21 billion in 2023 and is projected to reach USD 1.76 billion by 2031, growing at a CAGR of 4.9% during the forecast period 2024-2031".

The SMN1 gene replacement market is dominated by North America, with the United States leading due to early SMA diagnosis, favorable reimbursement, and strong adoption of gene therapies such as Zolgensma. Japan is emerging as a key market in the Asia-Pacific region, driven by government-backed initiatives for rare diseases and accelerated drug approvals. Both countries play a critical role in global market expansion.

Download your exclusive sample report today: https://www.datamintelligence.com/download-sample/smn1-gene-replacement-market?jd

Strategic Partnerships and M&A Activity Shaping the Future of the SMN1 Gene Replacement Market

• Novartis's OAV101 Intrathecal Zolgensma Partnership Moves Forward
In March 2025, Novartis disclosed positive Phase III data for its OAV101 IT gene therapy, a spinally administered version of Zolgensma targeting older SMA patients aged 2-17. The company plans regulatory filings in the first half of 2025, extending Zolgensma's market through licensing and development alliance strategies targeting older-age SMA cohorts.

• Novartis Positions Zolgensma for Expanded Patient Access via Global Screening Initiatives
At the 2025 MDA conference, Novartis reported that over 95% of U.S. infants diagnosed with SMA since newborn screening began have received Zolgensma, underscoring its collaborative efforts with healthcare systems and payers to enhance therapy rollout.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/smn1-gene-replacement-market?jd

Top Market Catalysts and Future Opportunities in the SMN1 Gene Replacement Therapy Space

1. Increasing Incidence and Early Diagnosis of Spinal Muscular Atrophy (SMA)
Wider adoption of newborn screening programs, especially in the U.S., Europe, and parts of Asia, is enabling earlier diagnosis of SMA. Early intervention with gene replacement therapies like Zolgensma has shown significantly better outcomes, creating demand for first-line curative treatments for SMA.

2. Expanding Clinical Use and Label Approvals for Zolgensma
Novartis's Zolgensma, currently approved for infants under two, is progressing toward intrathecal formulations for older pediatric patients aged 2-17. Regulatory expansion and age-agnostic use are major opportunities for revenue growth and global accessibility.

3. Growing Government and Payer Support for Rare Disease Therapies
Governments in the U.S., EU, and Japan are rolling out rare disease policies and funding frameworks, improving reimbursement for high-cost gene therapies. This financial backing supports wider adoption across private and public healthcare systems.

4. Technological Innovation in AAV-Based Gene Delivery
Advancements in adeno-associated virus (AAV) vectors, such as self-complementary AAV9, are improving delivery efficiency and reducing immunogenicity, enhancing long-term efficacy and safety of SMN1 gene therapies.

5. Strategic Collaborations to Scale Global Access
Companies like Novartis are forming alliances with hospitals, diagnostic labs, and patient advocacy groups to boost access and awareness in underserved regions. Such collaborations are paving the way for equitable global distribution of gene therapy for SMA.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=smn1-gene-replacement-market?jd

Competitive Landscape: Key Players Driving Innovation in SMN1 Gene Replacement Therapy

As per our analysis, Biogen, Novartis AG, F. Hoffmann-La Roche Ltd (Genentech), Ionis Pharmaceuticals, Inc., and Chugai Pharmaceutical Co., Ltd. are the prominent players.

The SMN1 gene replacement therapy market is led by Novartis, whose product Zolgensma remains the only FDA-approved gene therapy for SMA, capturing significant global market share.

As competition intensifies, companies focused on scalable manufacturing, regulatory expansion, and age-inclusive therapy development will maintain a competitive edge.

Unlock 360° Market Intelligence with DataM Subscription Services:
https://www.datamintelligence.com/reports-subscription

✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drug Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.